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ABSTRACT
Mefenamic acid, a BCS class II drug, displays high permeability and low solubility, thereby
exhibiting a poor dissolution profile. Hence to improve the solubility and dissolution rate of
Mefenamic acid, Hot Melt Extrusion (HME) technique was employed. The amorphous solid
dispersion matrix exhibited enhanced dissolution with desired release characteristics.
Hydroxypropylmethylcellulose acetate succinate (AquaSolve™ HPMC-AS HG) was used as a
carrier with the poloxamer (Kolliphor P407). The drug load was varied from 20% to 40% within
the blend. Drug and polymers were blended using a twin shell V-blender for 10 minutes and
extruded using an 11mm twin-screw co-rotating extruder (ThermoFisher Scientiﬁc, Waltham,
MA, USA). The processing conditions were selected by conducting pre-formulation studies, which
included thermogravimetric analysis (TGA) to determine the thermal degradation temperature of
mefenamic acid and selected polymers. Differential Scanning Calorimetry (DSC) was performed
to determine the Tg of the polymers and Tm of the API. The extruded strands were collected, milled
and sifted through a #30 sieve. This milled and sieved product was then subjected to DSC to
characterize the state of drug in solid dispersions. The drug content of the extrudates was observed
to be in acceptable range. To assess the drug release profile of the extrudates, in vitro dissolution
testing was conducted in pH 7.4, phosphate buffer. Scanning Electron Microscopy was performed
to study the morphology of the solid dispersions and Fourier Transform Infrared Spectroscopy was
also performed to make sure that the drug and polymers are compatible with each other.
Formulations containing Kolliphor P407 exhibited enhanced dissolution profiles compared to the
ii

pure Mefenamic acid and solid dispersions with plain HPMC-AS HG. The DSC results illustrated
the amorphous conversion of Mefenamic acid in the solid dispersions. The stability studies
indicated that the optimized formulation with 20% drug load was found to be stable and in
amorphous form with similar release profile after 3 months of study. Solid dispersions of
Mefenamic acid with improved dissolution rate were prepared using Hot Melt Extrusion
technology.
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CHAPTER 1: INTRODUCTION
Mefenamic acid (MA) is a Cyclooxygenase 1 and Cyclooxygenase 2 inhibitor and is
classified as a Non-Steroidal Anti-inflammatory Drug [1]. It is widely used in the treatment of
mild pain, specially dysmenorrhea [2]. The bioavailability of mefenamic acid is 90% but is often
influenced by water intake, primary site of absorption is small intestine, tmax is achieved between
2-4 hours and 2-3 days are needed to reach the steady state concentration of the drug [3].
Mefenamic acid also causes certain adverse effects in the gastrointestinal tract such as bleeding
and ulceration, the main reason behind these effects is believed to be its mechanism of action [4].
Mefenamic acid comes under class II of the Biopharmaceutical Classification System,
which means that it has low solubility and high permeability, hence its oral bioavailability is
highly dependent on its dissolution rate in the gastrointestinal tract [5,6]. If the solubility of a
drug is poor, it drastically affects the in vitro dissolution and ultimately affecting in vivo
absorption and bioavailability of the drug. Therefore, solubility of a drug plays a vital role in
attaining its therapeutic concentration. Furthermore, the side effects caused are also enhanced by
the poor solubility of the drug, attributing to the fact that dose frequency increases when the drug
is poorly soluble in GIT [7].
There has been a great advancement in the field of pharmaceutical sciences when it
comes to enhancing the solubility of drug substances, techniques like solid dispersions [8],
inclusion complex [9], ultra-rapid freezing process [10], melt sonocrystallization [11], solvent
change method [12], melt granulation technique [13], supercritical solvent are being used
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extensively.
Among these approaches, Hot Melt Extrusion is a reasonably new technique which has
brought various advantages over others [14]. Various perks of Hot Melt Extrusion include it
being a continuous process, its solvent free and thus could also be considered one of the most
economical techniques which has a very few processing steps and is devoid of drying steps. The
process of extrusion involves physically mixing the drug/s with the polymers and other
ingredients which are then pumped through a barrel at elevated temperature and pressure so as to
get a uniform product often referred to as extrudates [15,16]. The materials which are unstable at
higher temperatures may cause the process to malfunction and the product to degrade [17]. Upon
addition of some specific carriers and/or plasticizers, thermal stability of a drug can be improved
to a great extent, also promoting better extrusion processability while decreasing processing
temperatures [18].
Solubility of many hydrophobic drugs can be improved by introducing a hydrophilic
carrier into the formulation matrix, these might include PVP, HPMC or Eudragit [18]. Though
the solubilization capacity of these polymers might be interrupted because of supersaturation or
recrystallization [19]. This supersaturation phenomenon is exploited in this research using
HPMC AS HG as a carrier. The precipitation inhibiting effect of HPMC AS has been reported in
the literature [20,21].
Since HPMC AS HG solubilizes at a pH above 7, it presented a perfect environment to
hinder the drug release in acidic media. The poloxamer P407 (Kolliphor) is used in this study as
a solubility or dissolution enhancer which has a low melting point, surfactant properties and is
orally safe to be used [22,23,24,25].
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Design of Experiments (DoE) is an important tool used in the statistical analysis and plays a
vital role in the application of Quality by Design approach in both industrial and laboratory
based research setting. It has been observed that ever since ICH Q8 Guidelines highlighted the
use of DoE approaches in the scientific and industrial domain, there has been a significant rise in
the utilization of DoE. Furthermore, availability of various statistical and designing software at
scientists’ disposal added to the opportunities to exploit this approach at a much greater pace
[26]. The software used in this study was Design Expert 11, which is one of the latest versions of
the software by Stat-Ease, Inc.
The selection of design was based on the prediction based optimality criteria and the applied
approach was dependent on the drug dissolution studies, taking into account the crystallinity of
the formulations as observed via Differential Scanning Calorimetry. Staying as close as possible
to the above mentioned responses, Mixture Design of Experiment methodology was selected
[27]. Within Mixture DoE methodology, to minimize the average prediction variance over the
experimental region, I optimal criterion was given a go ahead [28].
In accordance to the I optimality criterion, if P1 is considered to be the average prediction of
variance of Design 1 and P2 is considered to be the average prediction of variance of Design 2,
then I-efficiency of Design 1 can be stated as; P2/P1 and vice versa for Design 2. If the value of
I-efficiency for Design 1 is larger than 1, it depicts that Design 1 is better than Design 2 as far as
average prediction variance is concerned. When D-optimal designs were compared with Ioptimal designs, it was found that in case of D-optimal designs the median variance of prediction
is about 50% larger than that of I-optimal designs. Furthermore, it was observed that the Iefficiency of I-optimal designs was higher (1.00) than D-optimal designs which gave a
confirmation for the effectiveness of I-optimal mixture design for this study [28].
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There were two main purposes of this study;
i)

To prepare HPMC AS HG based amorphous solid dispersions of mefenamic acid and
investigate the effect of Kolliphor® on the dissolution profiles using Hot Melt
Extrusion Technology.

ii)

Mefenamic acid, a BCS class II drug, displays high permeability and low solubility,
thereby exhibiting a poor dissolution profile. Hence Hot Melt Extrusion technique
was used to improve the solubility and dissolution rate of mefenamic acid.
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CHAPTER 2: MATERIALS AND METHODS
Mefenamic acid was purchased from TCI America, Portland, OR. Aquasolve HPMC AS
HG was received as a gift from Ashland, Kolliphor P407 was received as a gift from BASF.
Sodium hydroxide and potassium phosphate were purchased from Acros Organics. All other
chemicals used in this study were of analytical grade.
Thermogravimetric Analysis:
Thermogravimetric analysis is a method that is used to ascertain the thermal degradation
temperature of mefenamic acid and other components of the formulation. The equipment used in
this study was a Perkin Elmer, Pyris 1, Shelton, CT, USA. TGA was performed in the heating
range of 25°C - 300°C along with an accelerated rate of 10 °C/min. Nitrogen purge was set at 20
ml/min and approximately 5 mg of each sample was weighed in the platinum pan and analyzed
using the Pyris 1 software. The interpretation of TGA results is based on the weight loss of the
treated sample when compared to the initial weight.
Differential Scanning Calorimetry:
DSC analysis was performed to analyze the glass transition temperature and melting
point of pure ingredients and eleven different formulations. The instrument used was a TA
Instruments Discovery Series DSC 25, New Castle, DE, USA. Analysis was performed over the
temperature range of 25°C to 300°C at 10°C and the nitrogen purge was set at 20°C/min.
Samples were weighed accurately (around 5 mg) and filled in an aluminum pan, sealed with a
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hermetic lid. TRIOS software was used as a means to analyze the solid state characteristics and
thermal stability of the pure drug, polymers and the formulations.
Screening:
Screening studies were performed to get a better idea about setting the upper limit and
lower limit while designing the experiments. These studies included going higher and lower with
the extrusion temperature and testing the dissolution of the extrudates. The extrusion was
performed using a 11mm twin screw co-rotating extruder (Process 11® ThermoScientific,
Pittsburgh, PA, USA) at a lower temperature of up to 130°C with a 2.5 mm die insert at a screw
speed of 50 rpm. The temperature was also increased up to 190°C to check the changes in the
extrudates’ consistency.
The dissolution studies were performed with a pH 6.8 Phosphate Buffer solution using a Hanson
SR8 Plus Dissolution System (Chatsworth, CA) USP Type II (Paddle) Apparatus. The paddle
speed was set to 50 rpm and the samples were withdrawn at the time intervals of 15min,30min,
45min, 60min, 90min, 120min, 150min. The results of these screening studies played a vital role
in setting up the processing parameters while designing the final experiments.
Designing the Formulations:
Mixture designs consist of factors which are directly or inversely proportional to all the
ingredients of a mixture. They are usually used to predict responses associated with all the
formulations derived from that mixture and to predict exact ratios of all the components of that
mixture.28 In this study, the I-optimal mixture design has been used which is known to minimize
the average prediction variance. After selecting the optimal mixture design, the components of
the formulation are incorporated. The three components of the design were A- HPMCAS HG, BMefenamic acid and C- Kolliphor P407. The lower limit and upper limit of each component was
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set such that the mixture components of each run would add up to 100. The target profile of the
optimized formulation is described in table 1:
Table 1. Target profile.
ELEMENT/ATTRIBUTE

TARGET

Route of Administration

Oral

Dosage Form

Capsule

Assay

90-110%

Content Uniformity

USP <905>

Strength

100 mg

Stability

3 months

QTPP

CQA

accelerated stability
Dissolution

100% release

Solid State

Amorphous

Compatibility

Excipients

After the formulations were obtained, the response was added to the design. Since crystallinity of
the formulations was not quantified, there was only one response which could be used to
optimize the formulations. Drug release percentage was added as a response and further
optimization was based on the solid state characterization of these formulations. The processing
parameters used while performing extrusion are based on the results of the screening studies
which were performed before the actual study.
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Preparing the Formulations:
Table 2. Details of formulations

FORMULATION

% Mefenamic
Acid

% Aquasolve
HPMC AS HG

% Kolliphor
P407

F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11

20
20
20
30
30
30
35
40
40
40
40

80
70
60
70
60
50
50
60
55
50
40

0
10
20
0
10
20
15
0
5
10
20

After going through the pre-formulation data, processing parameters for hot melt extrusion were
finalized and extrusion process was carried out. Physical mixture of the formulations mentioned
in table 2 were prepared by weighing the exact amount of drug and the polymers according to the
formulation design and blending them together using a turbula tumbling blender (Globe Pharma
MaxiblendTM, New Brunswick, NJ, USA). These blended products were then extruded using a
11mm twin screw co-rotating extruder (Process 11® ThermoScientific, Pittsburgh, PA, USA). A
screw speed of 50 rpm with a standard screw configuration was employed for extrusion. A 2.5
mm die insert was used while extruding and the temperature settings have been mentioned in
table 3. Feed rate was set at 4 (approximately 1.5 gm/min) and torque was carefully observed all
throughout the process. The screw configuration is described in figure 1. The extrudates were
then milled using a laboratory grinder and sieved through ASTM #30 mesh. The sieved powder
was weighed according to the drug load and filled in hard gelatin capsules which were then used
8

for dissolution studies.

Figure1. Standard screw configuration of Twin Screw Hot Melt Extruder.
Table 3. Processing parameters for extrusion.
FORMULATION

F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11

Extrusion
Temperature
(°C)
160
150
140
160
160
160
160
160
160
160
160

9

RPM

Torque %

50
50
50
50
50
50
50
50
50
50
50

40
23
17
33
20
10
15
31
27
18
8

Fourier Transform Infrared Spectroscopy:
FTIR spectroscopy was used as a means to study the interaction between the drug and the
polymers in the extrudates. The equipment used in this study was an Agilent Technologies Cary
600 Series FTIR Spectrophotometer, Santa Clara, CA, USA. Samples of pure drug, polymers and
formulations were placed on the mirror surface and the data was collected and analyzed using the
Resolutions Pro software.
Scanning Electron Microscopy:
SEM study was performed to evaluate the surface morphology of the pure drug and
formulations. The equipment used to perform this study was a JEOL JSM 5600 SEM (JEOL,
Peabody, MA, USA) at an accelerated voltage of 5kV. Hummer Sputtering system (Anatech
Ltd., Springfield, VA, USA) was used to prepare the sample in a high vacuum evaporator.
Carbon pads were mounted on an aluminum base and the extrudates were powdered and placed
on these adhesive pads. This step was followed by sputter coating with gold in a specific work
chamber. After the gold coating, these samples were put under the microscope and the images
were clicked at 50X, 200X and 500X.
Content Uniformity:
Milled extrudates equivalent to 50 mg of pure drug were weighed and transferred into 50
ml volumetric flasks. 40 ml Methanol was added to the flask and sealed with a Parafilm. This
setup was sonicated for 20 minutes using a Branson 2800 Ultrasonic Bath (Cleanosonic,
Richmond, VA, USA) to solubilize the drug completely in methanol. Once it is solubilized,
volume was made up to the 50 ml mark using a pipette. Following this, 1 ml of drug-methanol
solution was pipetted out into a 20 ml glass vial and mixed with 9 ml methanol to dilute the
solution. It is further diluted to suitable dilutions and then analyzed at a wavelength of 285 nm
10

using a UV Visible Spectrophotometer.
Dissolution Studies:
Hanson SR8 Plus Dissolution System (Chatsworth, CA) USP Type II (Paddle) Apparatus
was used to carry out the in vitro dissolution studies. The milled extrudates and the pure drug
were weighed in accordance with the drug load equivalent to 100 mg mefenamic acid, sieved
through sieve #30 and filled in hard gelatin capsules. Dissolution studies were performed in pH
7.4 Phosphate Buffer dissolution media for a period of 150 minutes. These capsules were placed
in dissolution vessels filled with 900 ml buffer solution using sinkers. The temperature of the
water bath was maintained at 37 ± 0.5 °C and paddle speed was 50 rpm. 3 mL samples were
withdrawn from the dissolution vessels after 15min, 30min, 45min, 60min, 90min, 120min,
150min. The samples were withdrawn using a syringe, attached to it was a 10µ filter to keep out
all the solid particles and replaced with equal volume. The samples were diluted suitably and
analyzed using UV Visible Spectrophotometry.
Stability Studies:
The stability studies were conducted for three months based on the release profiles of all
the formulations. The formulations with 100% drug release were selected, which were F3, F7,
F9, F10. Three months accelerated stability studies were performed at RH 75% ± 5% and
temperature 40°C ± 2°C. Solid state characteristics were analyzed using DSC, drug content
uniformity and dissolution studies were carried out to make sure that the formulations remained
stable for 3 months. All the parameters used during these studies were kept same as they were
with initial samples. The Similarity Factor (f2) and Dissimilarity Factor (f1) were calculated
using the formulae provided here.
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CHAPTER 3: RESULTS AND DISCUSSIONS
Solid dispersions of mefenamic acid (20%, 30%, 35% and 40%) with varying ratios of
AquaSolve™ HPMC-AS HG and Kolliphor® P407 (0%, 10% and 20%) were successfully
prepared using hot melt extrusion technology. Formulations containing Kolliphor® P407
exhibited enhanced dissolution profiles compared to the pure mefenamic acid and solid
dispersions of plain HPMC-AS HG. The detailed account of the results from various studies has
been discussed here.
Thermogravimetric Analysis:
Thermogravimetric analysis was performed and since it was one of the very important
preformulation study, all the ingredients of the formulation were studied. TGA represents the
thermal degradation temperature of mefenamic acid to be around 238°C, which denotes that the
decomposition of mefenamic acid occurred at 238°C. It is same as it has been reported in the
literature [29]. The thermal degradation temperature of HPMC AS HG and Kolliphor P407 was
not detected when they were heated till 300°C. The processing temperature was less than the
degradation temperature of mefenamic acid to make sure that it does not degrade during
extrusion process. The TGA of mefenamic acid, HPMC AS HG and Kolliphor P407 is given in
figure 2.
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Differential Scanning Calorimetry:
DSC was performed at a temperature range of 25ºC to 300ºC. The thermogram obtained
showed two endothermic peaks of mefenamic acid at 174°C and 231°C which indicates that it
exists in two polymorphic forms. These two endothermic peaks correspond to conversion of
Form I to Form II and then melting of Form II (231°C) respectively [30]. The solid dispersions
show complete conversion to amorphous form hence improving the solubility of the formulation.
However, the DSC thermograms of SDs prepared using higher concentrations of MA showed a
low intensity peak. The crystalline peak of MA was either disappeared or shifted to lower
temperatures in case of different SDs. This observation indicated the partial conversion of MA
into amorphous form.

Figure 2. TGA of the drug and polymers.
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Fourier Transform Infrared Spectroscopy:
The FTIR spectra of all the samples, shown in figure 4, are consistent with the IR
spectrum of the pure mefenamic acid reference spectrum. The peaks at 1646, 1255 and 889
cm−1 are representing N-H amine bending, aromatic amine stretch and aromatic C=C bending,
respectively. As far as the solid dispersions of MA and Kolliphor P407 are concerned, there was
no significant difference observed when all assigned peaks were compared to the pure drug. The
only exception was the ether vibrations which shifted from 2910 cm-1 to a lower wavenumber of
2860 cm-1 to 2870 cm-1. This might be a result of hydrogen bonding with C=C in MA.29

Figure 3. DSC of pure components and formulations.
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Figure 4. FTIR of the drug and formulations.

Scanning Electron Microscopy:
The SEM images of the pure drug indicate that there are smaller crystalline particles
accumulated on and around the bigger crystal in case of pure MA. However, when the SEM
images of the amorphous solid dispersions were studied, it was found that the smaller crystalline
particles were completely absent. There is an absolute mixture of the drug and the polymer at
molecular level which can be clearly seen with the help of SEM images (Figure 5). This
observation further confirmed the conversion of MA to an amorphous form.
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F3

PURE MA
Figure 5. SEM images of the drug and selected formulation.
Content Uniformity:
The drug content uniformity of the formulations was calculated and the results were
found to be under the range of accepted parameters set by the USP. The prerequisite for dose
uniformity is achieved if the acceptance value of 10 units is less than or equal to L1%. In case the
acceptance value is higher, next 20 units are tested for the acceptance value, the conditions are
met if the ultimate acceptance value of all 30 units is less than or equal to L1% and no individual
content of any unit is less than (1 – L2*0.01) M nor more than (1 + L2*0.01) M. The value of L1
is 15.0 and L2 is 25.0, unless there is some other value described in individual monograph. In
other words, the preparation fails to comply with the test if more than three individual contents
are outside the limit of 85% to 115% of the average content or if one or more individual contents
are outside the limits of 75% to 125% of the average content [31].
Acceptance Value is calculated with the formula:
17

AV = |M - X̄| + ks
Here, M is the reference value which depends on the value of X̄, which is the mean of
individual contents. If the mean is ≥ 98.5% or ≤ 101.25%, then M = X̄ which would mean AV =
ks. If the mean is < 98.5%, then M = 98.5% and if the mean is > 101.5%, then M = 101.5%. k is
the acceptability constant and s is the standard deviation.
The drug content was in the range of 90.4% to 101% for all formulations, which is pretty
much under the specified values as it is described in the USP.
Dissolution Studies:
The in vitro release profile of the formulations was studied and it was observed that there
was a significant improvement in the release profile of formulations which contain poloxamer. It
was also clear that there was a decline in the release profiles of most of the formulations on
increasing the drug load. It was also noticeable that as the amount of poloxamer was increased,
drug release improved to some extent except a few cases where the drug release was enhanced
on increasing the drug load.
These behaviours may be attributed to a number of sub processes, the fact that the
wettability of the composition is enhanced when a hydrophilic carrier is added to the formulation
is one of those justifications. The wetting of hydrophobic surfaces of the MA-HPMCAS HG
solid dispersions is facilitated by the hydrophilic carrier, which in this case is poloxamer P407.
As a result, the release of MA from the solid dispersion is accelerated [32]. Moreover, the
hydrophilic carriers also reduce agglomeration and aggregation of the drug particles, facilitating
their contact with the dissolution medium which in turn enhances the dissolution rate. The
rationale behind the use of HPMCAS HG was its ability to hinder dissolution of the drug in an
acidic media, which was a very significant factor in this study since the drug release was targeted
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in the intestine [32]. The main reason for the targeted release of MA in the intestine is its
mechanism of action, as MA is a non-selective cox inhibitor and has been known to inhibit
Cyclooxygenase 1 when absorbed through stomach causing various side effects like abdominal
pain, constipation, diarrhoea and heartburn. These side effects could be curbed by following the
targeted absorption of MA through intestine, since its mechanism of action would be altered
when absorbed through intestine. It would then inhibit Cyclooxygenase 2, which will further
exhibit a conventional pain relieving effect without adding any drawbacks [33].
From figure 6 it can be observed that there is an agreement in increase of drug release
from the formulation with the increase in poloxamer concentration but only up to a certain
extent. This can be noticed from the difference in drug release profiles of formulations F10 and
F11. Formulation F10 with 40% drug load and 10% poloxamer displays a superior drug release
profile as compared to F11 with 40% drug load and 20% poloxamer. This observation can be
attributed to two main reasons. First, a higher concentration of surfactant (F11) leads to
formation of bigger micelles that leads to a lower surface area and hence stunned drug release as
observed by Enderberg et al [34]. Second, poloxamer has a capability of enhancing the viscosity
of the diffusion layer at a higher concentration. The increased viscosity of the diffusion layer due
to the gel forming capability of poloxamer in F11 may be responsible for the superior
performance of F10. This same pattern can be observed with formulations F5, F6, F7 because of
the higher drug load and varying surfactant ratios [35]. Formulations F2 and F3 do not follow
this trend because of a low drug load which is not affected by the hindering property of
poloxamer 407.
Since this study involved enhancing the dissolution profile at a specific site, screening
studies were performed to make sure that a minimum amount of drug would be released at a pH
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below 7. When the drug dissolution studies were performed using the same formulations with a
pH 6.8 Phosphate Buffer, it was observed that the drug release was barely 35% as shown in table
4. Therefore, it could be further stated that if the dissolution studies were to be performed at an
acidic pH, the drug release would be retarded to a greater extent.
Table 4. Drug release at pH 6.8 phosphate buffer
Time
0
15
30
45
60
90
120
150

Pure MA
0
0.21
0.85
1.77
1.98
2.91
3.77
4.04

F1
0
7.09
14.60
20.26
23.92
27.48
30.60
31.78

F2
0
0.28
3.36
15.29
24.36
30.90
34.09
34.36

F3
0
1.34
8.70
16.87
21.88
27.86
33.49
35.96

As far as the extrusion parameters were concerned, the screening studies presented some
useful insights which were handy while deciding on the final parameters. It was observed that on
increasing the extrusion temperature above 160°C, the extrudates started losing their firmness
and went on to get liquefied on increasing the temperature to 190°C. On the other hand, when the
temperature was decreased below 140°C, the torque went beyond limit and since it could harm
the extruder the temperature was not decreased below 140°C.
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Figure 6. Release profiles of MA and all formulations

Figure 7. Release profiles of 20% MA formulations
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Figure 8. Release profiles of 30% MA formulations

Figure 9. Release profiles of 40% MA formulations
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Statistical Analysis:

Table 5. Analysis of variance.
Source
Model
⁽¹⁽Linear
Mixture
AB
AC
BC
Residual
Lack of Fit
Pure Error
Cor Total

Sum of
Squares
1381.91
883.19

df

37.34
491.12
132.60
245.87
245.87
0.0000
1627.78

1
1
1
6
5
1
11

5
2

Mean
Square
276.38
441.60

F-value

p-value

6.74
10.78

0.0189
0.0103

37.34
491.12
132.60
40.98
49.17
0.0000

0.9113
11.99
3.24

0.3766
0.0134
0.1221

significant

The Model F-value of 6.74 implies the model is significant. There could only be a 1.89%
chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicated
that the model terms are significant. In this case A, B, AC are significant model terms. Values
greater than 0.1000 indicate the model terms are not significant. If there are many insignificant
model terms (not counting those required to support hierarchy), model reduction might improve
this model.
Table 6. Fit statistics
Std. Dev.
Mean
C.V. %

6.40
92.96
6.89

R²
Adjusted R²
Predicted R²
Adeq Precision

0.8490
0.7231
-0.0164
6.6442

A negative Predicted R² implies that the overall mean may be a better predictor of the
response than the current model. In some cases, a higher order model may also predict better.
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Adeq Precision measures the signal to noise ratio. A ratio greater than 4 is desirable. Here the
ratio of 6.644 indicates an adequate signal. This model can be used to navigate the design space.
Table 7. Coefficient in terms of coded factors
Component
A-HPMC ASHG
B-Mefenamic
acid
C-Poloxamer
P407
AB
AC
BC

Coefficient
Estimate
76.28

df
1

Standard
Error
5.67

95% CI
Low
62.42

95% CI
High
90.15

VIF
2.71

106.59

1

33.94

23.53

189.64

39.10

9.26

1

36.18

-79.27

97.79

36.94

-60.91
223.57
171.81

1
1
1

63.80
64.58
95.51

-217.03
65.55
-61.90

95.21
381.59
405.51

19.11
16.23
27.88

The coefficient estimate represents the expected change in response per unit change in
factor value when all remaining factors are held constant. The intercept in an orthogonal design
is the overall average response of all the runs. The coefficients are adjustments around that
average based on the factor settings. When the factors are orthogonal the VIFs are 1; VIFs
greater than 1 indicate multi-colinearity, the higher the VIF the more severe the correlation of
factors. As a rough rule, VIFs less than 10 are tolerable.
When the Predicted versus Residual graph was analysed, it was observed that all the
formulations are in linearity and the variability was uniform all along the axis. There was no
curvature or outliers and hence the assumptions of this model are believed to be true. The
variance was constant with the mean all throughout the graph and the constant variance
assumption was not violated.
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Figure 10. Graphs of actual, predicted and residual data.
The regression graphs given in figure 10 describe the relationship between the
independent variables and the dependent variables in the formulation. As it can be very easily
noticed from the Actual versus Predicted graph, there is a positive relationship between the
independent and the dependent variables in the formulation. The response used in this prediction
was % drug release and with the help of regression analysis, it could be further confirmed that
the formulations were significantly influenced by poloxamer 407. The formulations with 0%
poloxamer 407 can be seen at the lower end of the graph while the formulations with some
amount of poloxamer 407 are at the top end of the graph.
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Figure 11. Numerical Optimization
Figure 11 demonstrated that there could be 42 possible formulations within the limits of
this design that could give a 100% drug release and the optimized formulation can be selected
from these 42 formulations. Formulation #34 could be selected as an optimized formulation
owing to fact that it closely resembles formulation F3. Furthermore, formulation F3 had
completely converted into amorphous form, was compatible to the ingredients and had
acceptable drug content uniformity.
Stability studies:
The thermogram obtained after DSC (Figure 12) showed that there is no recrystallization
peak in case of formulation F3, while there appears to be some recrystallization in formulations
F7, F9 and F10. The drug content uniformity was checked and it was found to be within the
acceptable range in accordance to the USP. The optimized formulation was also evaluated for its
drug release profile by performing dissolution studies, and the release profile can be seen in
Figure 13. The Similarity Factor (f2) and dissimilarity Factor (f1) were calculated using the
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formulae and they were found to be well within the range of a stable formulation [36].
Table 8. Drug content after 3 months accelerated stability study
F33
93.1888

F77
98.452

F9
F10
106.6047 102.8896

Table 9. Table of similarity and dissimilarity factors after accelerated stability studies.
Formulations

f1

f2

F3

5.99

62.86

F7

9.05

56.66

F9

5.91

62.28

F10

5.55

64.89

Figure 12. DSC thermograms of the stability samples
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Figure 13. Release profiles after accelerated stability studies.

As far as the optimized formulation was concerned, there was only one formulation
which could possibly be considered as an optimized formulation. It could be clearly observed
from the release profiles, solid state characterization and stability studies that formulation F3 is
the one which had a 100% drug release, had completely converted into amorphous form and
remained stable after 3 months of accelerated stability studies.
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CHAPTER 4: CONCLUSION
The dissolution of mefenamic acid in HPMCAS HG solid dispersions was observed to be
increased. Furthermore, addition of Kolliphor® P407 enhanced the dissolution rate compared to
pure mefenamic acid but on increasing the drug load above 20%, the poloxamer started forming
bigger micelles inhibiting the drug release after reaching Critical Micelle Concentration (CMC).
Mefenamic acid was converted into an amorphous form, which facilitated the increased rate of
dissolution. FTIR data reveal that the drug and polymers studied were compatible. Stability
studies showed that formulation F3 was stable after 3 months of accelerated stability study at RH
75% ± 5% and temperature 40°C ± 2°C. Therefore, it was confirmed that F3 could be considered
the optimized formulation. Solid dispersions of mefenamic acid with improved dissolution rate
were prepared using hot melt extrusion technology.
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